<DOC>
	<DOCNO>NCT00855062</DOCNO>
	<brief_summary>Purpose : The purpose study assess safety effectiveness minocycline , antibiotic , treatment Human immunodeficiency virus ( HIV ) -associated cognitive impairment Uganda . Study Design : Treatment , 24-week Randomized , Placebo-Controlled , Double-Blind Phase Optional 24-week Open Label Phase Subjects cluster differentiation 4 ( CD4 ) Count 251-350 Range - Arm 1 : Minocycline 100 mg orally every 12 hour ( 50 subject ) - Arm 2 : Matching placebo orally every 12 hour ( 50 subject ) Primary Objective : · To examine whether minocycline treatment improve cognitive performance 24 week compare baseline Secondary Objectives : - To examine whether minocycline treatment 24 week safe well-tolerated individual HIV-associated cognitive impairment - To examine whether minocycline treatment 48 week safe well-tolerated individual HIV-associated cognitive impairment - To examine whether minocycline treatment 24 week improve functional impairment</brief_summary>
	<brief_title>Minocycline HIV+ Cognitive Impairment Uganda</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>HIV infection prior study entry Naïve antiretroviral regimen ineligible receive antiretroviral therapy cluster differentiation 4 ( CD4 ) criteria Uganda Negative serum urine pregnancy test woman childbearing potential Willingness use birth control Age 1865 year AIDS Dementia Scale Stage 0.5 OR 1 Impaired cognitive performance evidence International HIV Dementia Scale ( HDS ) define protocol Ability sit stand swallow intact capsule 8ounce glass water Ability willingness subject legal guardian/ representative give write informed consent Resident within 20km radius Kampala city Current cancer basal cell carcinoma , situ carcinoma cervix , Kaposi 's sarcoma without evidence visceral involvement require systemic chemotherapy Severe premorbid psychiatric illness , include schizophrenia major depression , investigator 's opinion , likely interfere study compliance Active symptomatic AIDSdefining opportunistic infection within 45 day prior study entry Confounding neurological disorder define protocol Central nervous system infection cancer define protocol Systemic lupus Thyroid disease diagnose within 24 week prior entry Breastfeeding Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion investigator History allergy/sensitivity minocycline tetracycline formulation Any clinically significant condition laboratory abnormality , opinion investigator , would interfere subject 's ability participate study . This include individual find HIV dementia scale stage 3 4 . Any esophageal condition would interfere swallow study medication Use exclude drug define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Human immunodeficiency virus ( HIV )</keyword>
	<keyword>HIV associate cognitive impairment</keyword>
	<keyword>HIV dementia</keyword>
	<keyword>Uganda</keyword>
	<keyword>Acquired immune deficiency syndrome ( AIDS )</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>